APP
AIMT

Avantax Planning Partners’s Aimmune Therapeutics AIMT Stock Holding History

Avantax Planning Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-121
Closed -$3K – 1367
2018
Q3 		$3K Buy
+121
New +$3.42K ﹤0.01% 1302
2018
Q2 		– Sell
-157
Closed -$5K – 1712
2018
Q1 		$5K Buy
+157
New +$5.53K ﹤0.01% 1381

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Avantax Planning Partners's AIMT Position: Q4 2018 in Review

Avantax Planning Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 121 shares — an estimated $3K sold.

Avantax Planning Partners first reported a position in AIMT in Q1 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2018. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

  • Avantax Planning Partners reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 121 Aimmune Therapeutics shares in Q4 2018, an estimated $3K.
  • Avantax Planning Partners first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Aimmune Therapeutics position peaked at $5K in Q1 2018.
  • 132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.